US FDA Lifts Clinical Hold for Audentes’ Gene Therapy AT132: Astellas

Audentes Therapeutics, Astellas Pharma’s US subsidiary, has been notified by the US FDA of the lifting of the clinical hold for the PII ASPIRO study of its gene therapy AT132 in patients with X-linked myotubular myopathy (XLMTM) after the submission...read more